Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2021 Aug 1;27(15):4139-4141.
doi: 10.1158/1078-0432.CCR-21-1011. Epub 2021 May 27.

Myeloid Resistance is not Futile: Biomarkers of Immunotherapy in Bladder Cancer

Charles G Drake  1   2
Affiliations
Comment

Myeloid Resistance is not Futile: Biomarkers of Immunotherapy in Bladder Cancer

Charles G Drake. Clin Cancer Res. .

Abstract

The majority of patients with urothelial cancer do not respond to immune checkpoint blockade directed at the PD-(L)1 axis. Recently, robust profiling data were used to derive predictive biomarker signatures for both protumorigenic immunity and adaptive antitumor immunity; combining these has greater predictive power than either alone. Clinically, these results suggest that myeloid cells may be primary drivers of nonresponsiveness in urothelial cancer.See related article by Wang et al., p. 4287.

PubMed Disclaimer

Comment on

References

    1. Wang L, Sfakianos JP, Beaumont KG, Akturk G, Horowitz A, Sebra RP, et al. Myeloid cell-associated resistance to PD-1/PD-L1 blockade in urothelial cancer revealed through bulk and single-cell RNA sequencing. Clin Cancer Res. 2021;27:4287–300.
    1. Aggen DH, Drake CG. Biomarkers for immunotherapy in bladder cancer: a moving target. J Immunother Cancer. 2017;5:94.
    1. Ayers M, Lunceford J, Nebozhyn M, Murphy E, Loboda A, Kaufman DR, et al. IFN-gamma-related mRNA profile predicts clinical response to PD-1 blockade. J Clin Invest. 2017;127:2930–40.
    1. McLaughlin J, Han G, Schalper KA, Carvajal-Hausdorf D, Pelekanou V, Rehman J, et al. Quantitative assessment of the heterogeneity of PD-L1 expression in non-small-cell lung cancer. JAMA Oncol. 2016;2:46–54.
    1. Perez-Ruiz E, Minute L, Otano I, Alvarez M, Ochoa MC, Belsue V, et al. Prophylactic TNF blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy. Nature. 2019;569:428–32.

Publication types

Substances

LinkOut - more resources